Chronic vs. Intermittent Therapy for Toxoplasma Encephalitis: Highlights of Neurological Research from the VIII International Conference on AIDS, Amsterdam, July 19-24, 1992

Chronic vs. Intermittent Therapy for Toxoplasma Encephalitis: Highlights of Neurological Research from the VIII International Conference on AIDS, Amsterdam, July 19-24, 1992

Seattle Treatment Education Project: STEP Perspective - Volume 4, Number 3 - October 1992
Lyn Frumkin, M.D., Ph.D.

Once a person is treated for HIV-related Toxoplasma encephalitis, continued drug treatment is usually given to keep the infection "suppressed" and prevent recurrence. Evaluating the same 63 persons with Toxoplasma encephalitis in the aforementioned study, another group at the University of Toronto (Dr. J. Fong) confirmed that continued treatment on a daily basis is associated with a much lower relapse rate (eight of 46 or 17 percent) than intermittent treatment given three times weekly (five of seven or 70 percent; average relapse time 10 months).
9210
STEP4320

Always watch for outdated information. This article first appeard in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1992 - Seattle Treatment Education Project (STEP) - All rights reserved. Noncommercial reproduction is encouraged. STEP is published four times a year by the Seattle Treatment Education Project, 127 Broadway East, 3rd Floor, Seattle, WA 98102. Email: step100@aol.com STEP web page

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1992. AEGIS.